Monfrini Marianna, Donzelli Elisabetta, Rodriguez-Menendez Virginia, Ballarini Elisa, Carozzi Valentina Alda, Chiorazzi Alessia, Meregalli Cristina, Canta Annalisa, Oggioni Norberto, Crippa Luca, Avezza Federica, Silvani Sara, Bonandrini Barbara, Figliuzzi Marina, Remuzzi Andrea, Porretta-Serapiglia Carla, Bianchi Roberto, Lauria Giuseppe, Tredici Giovanni, Cavaletti Guido, Scuteri Arianna
Experimental Neurology Unit and Milan Center for Neuroscience, School of Medicine and Surgery, University Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy; PhD Neuroscience Program, University Milano-Bicocca, via Cadore 48, 20900 Monza, Italy.
Experimental Neurology Unit and Milan Center for Neuroscience, School of Medicine and Surgery, University Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.
Exp Neurol. 2017 Feb;288:75-84. doi: 10.1016/j.expneurol.2016.11.006. Epub 2016 Nov 13.
Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.
1型糖尿病通常通过外源性胰岛素给药进行治疗。尽管进行了治疗，但糖尿病非常常见的一个长期后果是致残性疼痛性周围神经病变的发生。胰岛移植是一种先进的替代治疗方法，但其临床应用仍然非常有限，主要是因为完成该手术需要大量胰岛，且胰岛短期存活率较低。一种提高胰岛移植效果的有趣方法是间充质干细胞（MSC）的共移植，间充质干细胞是已知的能够支持不同细胞群体存活的成体干细胞。在这项概念验证研究中，我们使用糖尿病体内模型证明，同种异体间充质干细胞能够减少糖尿病大鼠实现血糖控制所需的胰岛数量，总体而言，其对糖尿病神经病变具有积极作用，可减轻疾病诱导后出现的所有神经病变体征。控制血糖所需胰岛数量的减少以及疼痛性神经病变的消退，使得间充质干细胞共移植成为一种非常有前景的工具，可提高胰岛移植治疗糖尿病的临床可行性。
